Epoetin alfa + Standard of Care
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hemostasis, Surgical
Conditions
Hemostasis, Surgical
Trial Timeline
Aug 1, 2006 → Feb 1, 2008
NCT ID
NCT00350519About Epoetin alfa + Standard of Care
Epoetin alfa + Standard of Care is a approved stage product being developed by Johnson & Johnson for Hemostasis, Surgical. The current trial status is terminated. This product is registered under clinical trial identifier NCT00350519. Target conditions include Hemostasis, Surgical.
What happened to similar drugs?
0 of 2 similar drugs in Hemostasis, Surgical were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00350519 | Approved | Terminated |
Competing Products
4 competing products in Hemostasis, Surgical
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| FS VH S/D 500 s-apr, 60-seconds polymerization time + FS VH S/D 500 s-apr, 120-seconds polymerization time | Baxter | Phase 2 | 32 |
| Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) | Baxter | Phase 3 | 37 |
| TISSEEL Lyo | Baxter | Phase 3 | 37 |
| Human thrombin + Bovine thrombin | Grifols | Phase 2 | 32 |